Exemestane

Generic Name: Exemestane

Brand Names: Aromasin

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₄O_₂

CAS Number: 107868-30-4

Unique Ingredient Identifier: NY22HMQ4BX

Advanced Drug Monograph

Access comprehensive pharmacological analysis, clinical applications, and therapeutic considerations.

Background: Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal women. It irreversibly binds to the active site of the enzyme resulting in permanent inhibition.

Indication: For the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.

Associated Conditions: Stage I Breast Cancer, Refractory, advanced Breast cancer

Clinical Trials

Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer

Phase 2

Active, not recruiting

Conditions: Atypical Hyperplasia
Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma

Interventions: Drug: Exemestane
Other: Laboratory Biomarker Analysis
Other: Pharmacokinetic Study
Other: Questionnaire Administration

First Posted Date: 2017-10-03

Last Posted Date: 2025-01-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT03300557

Locations: 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States
🇺🇸
University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin, United States

Phase 2 Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer

Phase 2

Completed

Conditions: Advanced or Recurrent Breast Cancer

Interventions: Drug: Entinostat(Placebo)
Drug: Entinostat
Drug: Exemestane

First Posted Date: 2017-09-25

Last Posted Date: 2022-06-21

Lead Sponsor: Kyowa Kirin Co., Ltd.

Target Recruit Count: 133

Registration Number: NCT03291886

Locations: 🇯🇵
Tsukuba University Hospital, Tsukuba, Ibaraki, Japan
🇯🇵
National Cancer Center Hospital, Chuo, Tokyo, Japan
🇯🇵
Toranomon Hospital, Minato, Tokyo, Japan

and more 25 locations

A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

Phase 1

Completed

Conditions: Breast Neoplasms

Interventions: Drug: Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody
Drug: Ipatasertib
Drug: Entinostat
Drug: Fulvestrant
Drug: Bevacizumab
Drug: Exemestane
Drug: Abemaciclib
Drug: Tamoxifen

First Posted Date: 2017-09-12

Last Posted Date: 2024-10-21

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 138

Registration Number: NCT03280563

Locations: 🇺🇸
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
Univ of Pittsburgh Sch of Med; Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States

and more 24 locations

Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients

Phase 2

Completed

Conditions: Breast Neoplasms

Interventions: Drug: Perjeta Injectable Product
Drug: Herceptin
Drug: Tamoxifen
Drug: Paclitaxel
Drug: Epirubicin
Drug: Cyclophosphamide
Drug: Anastrozole
Drug: Letrozole
Drug: Exemestane
Drug: Leuporelin acetate
Drug: Leuprorelin acetate
Drug: Goserelin
Diagnostic Test: Biopsy
Procedure: Surgery

First Posted Date: 2017-09-05

Last Posted Date: 2024-04-17

Lead Sponsor: Palleos Healthcare GmbH

Target Recruit Count: 257

Registration Number: NCT03272477

Locations: 🇩🇪
Evangelisches Krankenhaus Bethesda Mönchengladbach, Mönchengladbach, Germany

Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer

Phase 4

Withdrawn

Conditions: HER2/Neu Negative
Invasive Breast Carcinoma
Postmenopausal
Stage 0 Breast Cancer
Stage IA Breast Cancer

Interventions: Drug: Anastrozole
Drug: Exemestane
Other: Laboratory Biomarker Analysis
Drug: Letrozole
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Drug: Tamoxifen Citrate
Drug: Toremifene Citrate

First Posted Date: 2017-08-03

Last Posted Date: 2018-12-27

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT03238703

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy

Phase 4

Terminated

Conditions: Breast Neoplasm

Interventions: Drug: Palbociclib
Drug: Fulvestrant
Drug: Anastrozole
Drug: Letrozole
Drug: Exemestane

First Posted Date: 2017-07-18

Last Posted Date: 2022-01-06

Lead Sponsor: Palleos Healthcare GmbH

Target Recruit Count: 532

Registration Number: NCT03220178

Locations: 🇩🇪
University Hospital Mainz, Mainz, Germany

Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer
Invasive Breast Cancer

Interventions: Drug: Anastrozole
Drug: Letrozole
Drug: Exemestane
Drug: Tamoxifen

First Posted Date: 2017-07-17

Last Posted Date: 2025-04-29

Lead Sponsor: Medical College of Wisconsin

Target Recruit Count: 37

Registration Number: NCT03219476

Locations: 🇺🇸
Froedtert Hospital, Milwaukee, Wisconsin, United States

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

Phase 2

Active, not recruiting

Conditions: Advanced Breast Carcinoma
HER2-Positive Breast Carcinoma
Anatomic Stage III Breast Cancer AJCC v8
Anatomic Stage IV Breast Cancer AJCC v8
HER2-positive Breast Cancer

Interventions: Drug: Denifanstat
Drug: Anastrozole
Procedure: Echocardiography
Drug: Exemestane
Drug: Paclitaxel
Drug: Fulvestrant
Biological: Trastuzumab
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Drug: Letrozole
Procedure: Biospecimen Collection
Procedure: Biopsy

First Posted Date: 2017-06-07

Last Posted Date: 2025-02-26

Lead Sponsor: Mayo Clinic

Target Recruit Count: 19

Registration Number: NCT03179904

Locations: 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States